Revolution Medicines Finalizes Upsized $1.92 Billion Capital Raise via Convertible Notes and Common Stock Offerings

summarizeSummary

Revolution Medicines finalized the pricing for its upsized concurrent public offerings, raising approximately $1.92 billion in net proceeds through $500 million in convertible senior notes and $1.435 billion in common stock, strategically timed after recent positive clinical trial results.

check_boxKey Events · Financing and Capital Events · RVMD

• Upsized Capital Raise Finalized

  Revolution Medicines finalized its concurrent public offerings, raising approximately $1.92 billion in net proceeds. This includes $500 million from 0.50% convertible senior notes due 2033 and $1.435 billion from a common stock offering (excluding the underwriters' option).

• Convertible Notes Priced at Premium

  The $500 million convertible senior notes have an initial conversion price of approximately $198.80 per share, a significant premium over the common stock's last reported sale price of $147.01 on April 14, 2026.

• Common Stock Offering at Moderate Discount

  The common stock offering consists of 10,563,381 shares (plus an option for 1,584,506 additional shares) priced at $142.00 per share, representing a moderate discount to the prior day's closing price.

• Strategic Timing Post-Positive Clinical Data

  This substantial capital raise is strategically timed following recent announcements of highly positive late-stage clinical trial results and the commencement of a global Phase 3 trial for daraxonrasib, capitalizing on positive market sentiment.

auto_awesomeAnalysis · RVMD · Life Sciences

Revolution Medicines has finalized the terms for a substantial capital raise, securing approximately $1.92 billion in net proceeds through a concurrent offering of $500 million in convertible senior notes and $1.435 billion in common stock. This upsized offering follows closely on the heels of highly positive late-stage clinical trial results for its experimental oral drug, daraxonrasib, and the commencement of a global Phase 3 trial. The convertible notes are priced at an initial conversion price of approximately $198.80 per share, representing a significant premium to the common stock's last reported sale price of $147.01 on April 14, 2026, indicating strong investor confidence in the company's future prospects. While the common stock offering is priced at a moderate discount of $142.00 per share, the overall capital infusion is substantial, providing significant financial runway for general corporate purposes, including accelerated research and development, potential commercialization efforts, and strategic acquisitions. The combined offerings could result in a potential dilution of up to 7.44% if all convertible notes are converted and the common stock underwriters' option is fully exercised. This strategic move, capitalizing on recent positive news and trading near 52-week highs, significantly strengthens the company's balance sheet to advance its oncology pipeline.